31.20
+0.04(+0.13%)
Currency In USD
| Previous Close | 31.16 |
| Open | 31.06 |
| Day High | 31.45 |
| Day Low | 30.39 |
| 52-Week High | 31.45 |
| 52-Week Low | 11.13 |
| Volume | 1.28M |
| Average Volume | 2.33M |
| Market Cap | 3.82B |
| PE | -91.76 |
| EPS | -0.34 |
| Moving Average 50 Days | 23.99 |
| Moving Average 200 Days | 17.13 |
| Change | 0.04 |
If you invested $1000 in Arcutis Biotherapeutics, Inc. (ARQT) since IPO date, it would be worth $1,431.19 as of December 07, 2025 at a share price of $31.2. Whereas If you bought $1000 worth of Arcutis Biotherapeutics, Inc. (ARQT) shares 3 years ago, it would be worth $1,839.62 as of December 07, 2025 at a share price of $31.2.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
FDA Accepts Supplemental New Drug Application for Arcutis’ ZORYVE® (roflumilast) Cream 0.3% for the Treatment of Plaque Psoriasis in Children Ages 2 to 5
GlobeNewswire Inc.
Nov 17, 2025 1:00 PM GMT
Prescription Drug User Fee Act (PDUFA) target action date set for June 29, 2026If approved, ZORYVE cream 0.3% would be the first and only topical PDE4 inhibitor indicated for plaque psoriasis in children as young as 2 WESTLAKE VILLAGE, Calif., Nov.
Arcutis Completes Enrollment in INTEGUMENT-INFANT Phase 2 Study Evaluating ZORYVE® (roflumilast) Cream 0.05% in Infants with Atopic Dermatitis
GlobeNewswire Inc.
Nov 13, 2025 1:00 PM GMT
Investigational ZORYVE cream 0.05% was formulated for the delicate skin of infants and young children with mild to moderate atopic dermatitisTopline results anticipated in Q1 2026The U.S. FDA approved ZORYVE cream 0.05% for the treatment of mild to m
Arcutis Announces Publication of Positive Long-Term Safety and Efficacy Data of ZORYVE® (roflumilast) Foam 0.3% in Individuals with Seborrheic Dermatitis in American Journal of Clinical Dermatology
GlobeNewswire Inc.
Nov 04, 2025 1:00 PM GMT
ZORYVE foam 0.3% was safe, well-tolerated, and demonstrated durable and continuously improving efficacy in the treatment of seborrheic dermatitis up to 52 weeksOnce-daily ZORYVE foam 0.3% is approved to treat seborrheic dermatitis in adults and adole